Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects

[1]  R. Kahn,et al.  Serotonin receptor sensitivity in major depression , 1990, Biological Psychiatry.

[2]  W. Cahn,et al.  Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects , 1990, Psychiatry Research.

[3]  G. Kennett,et al.  m-CPP: a tool for studying behavioural responses associated with 5-HT1c receptors. , 1990, Trends in pharmacological sciences.

[4]  M. J. Norušis,et al.  SPSS advanced statistics user's guide , 1990 .

[5]  R. Glennon,et al.  Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. , 1989, European journal of pharmacology.

[6]  D. Murphy,et al.  Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[7]  D. Murphy,et al.  Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. , 1989, Archives of general psychiatry.

[8]  G. Kennett,et al.  Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. , 1989, European journal of pharmacology.

[9]  I. Lucki,et al.  Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. , 1989, The Journal of pharmacology and experimental therapeutics.

[10]  S. Peroutka,et al.  1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain , 1989, Biological Psychiatry.

[11]  C. Bethea,et al.  Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion , 1989, Neuropharmacology.

[12]  D. Hoyer.  Functional correlates of serotonin 5-HT1 recognition sites. , 1988, Journal of receptor research.

[13]  P. Conn,et al.  Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. , 1987, The Journal of pharmacology and experimental therapeutics.

[14]  L. D. van de Kar,et al.  Differential effects of serotonin (5-HT1A and 5-HT2) agonists and antagonists on renin and corticosterone secretion. , 1987, Neuroendocrinology.

[15]  P. Cowen,et al.  L‐Tryptophan and prolactin release: Evidence for interaction between 5‐HT1 and 5‐HT2 receptors , 1986 .

[16]  Y. Gelders,et al.  The Influence of Ritanserin, a Serotonin Antagonist, in Anxiety Disorders: A Double-blind Placebo-controlled Study versus Lorazepam , 1985, Pharmacopsychiatry.

[17]  T. Insel,et al.  Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. , 1984, Life sciences.

[18]  R. Fuller,et al.  Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine. , 1983, Life sciences.

[19]  H. Meltzer,et al.  Effect of serotonin precursors and serotonin agonists on plasma hormone levels. , 1982, Advances in biochemical psychopharmacology.

[20]  R. W. Turkington,et al.  Stimulation of human prolactin secretion by intravenous infusion of L-tryptophan. , 1973, The Journal of clinical investigation.